PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
Int J Clin Oncol. 2024 Mar 29. doi: 10.1007/s10147-024-02510-6. Online ahead of print.NO ABSTRACTPMID:38551728 | DOI:10.1007/s10147-024-02510-6 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Noriomi Matsumura Masaki Mandai Source Type: research
PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
Int J Clin Oncol. 2024 Mar 29. doi: 10.1007/s10147-024-02510-6. Online ahead of print.NO ABSTRACTPMID:38551728 | DOI:10.1007/s10147-024-02510-6 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Noriomi Matsumura Masaki Mandai Source Type: research
PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
Int J Clin Oncol. 2024 Mar 29. doi: 10.1007/s10147-024-02510-6. Online ahead of print.NO ABSTRACTPMID:38551728 | DOI:10.1007/s10147-024-02510-6 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Noriomi Matsumura Masaki Mandai Source Type: research
PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
Int J Clin Oncol. 2024 Mar 29. doi: 10.1007/s10147-024-02510-6. Online ahead of print.NO ABSTRACTPMID:38551728 | DOI:10.1007/s10147-024-02510-6 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Noriomi Matsumura Masaki Mandai Source Type: research
Cancers, Vol. 16, Pages 1333: Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine & mdash;A Retrospective Analysis
In conclusion, our study confirms the efficacy and safety of AZA in a real-world population and identifies potential biomarkers for response and survival. (Source: Cancers)
Source: Cancers - March 29, 2024 Category: Cancer & Oncology Authors: Kamil Wi śniewski Katarzyna Pruszczyk-Matusiak Bartosz Pu ła Ewa Lech-Mara ńda Joanna G óra-Tybor Tags: Article Source Type: research
PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
(Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - March 29, 2024 Category: Cancer & Oncology Source Type: research
Tripartite prehabilitation of patients with acute myeloid leukaemia and high-risk myelodysplastic syndromes during intensive chemotherapy before allogeneic haematopoietic stem cell transplantation (COHABILIT): protocol for an innovating prospective multicentre study
Objectives
Acute myeloid leukaemia (AML) and high-risk myelodysplastic syndromes (MDS) are often treated with intensive chemotherapy followed by allogeneic haematopoietic stem cell transplantation (allo-HSCT). The pretransplant treatment results in a general deterioration of the patient’s health and quality of life. Furthermore, allo-HSCT can be responsible for significant toxicity with risks of graft-versus-host disease (GvHD). Developing strategies to prevent physical deconditioning, undernutrition and psychological distress could help maintain a satisfactory general state of health before transplantation and thus ...
Source: BMJ Open - March 29, 2024 Category: General Medicine Authors: Saillard, C., Cuvelier, S., Villaron-Goetgheluck, C., Boher, J.-M., Almeida-Lopez, L., Le Corroller, A.-G., Denis, P., Rivieccio, C., Calvin, S., Vey, N., Bannier-Braticevic, C. Tags: Open access, Oncology Source Type: research
Cancers, Vol. 16, Pages 1320: Characterization of CD34+ Cells from Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Using a t-Distributed Stochastic Neighbor Embedding (t-SNE) Protocol
Rainer Haas
Using multi-color flow cytometry analysis, we studied the immunophenotypical differences between leukemic cells from patients with AML/MDS and hematopoietic stem and progenitor cells (HSPCs) from patients in complete remission (CR) following their successful treatment. The panel of markers included CD34, CD38, CD45RA, CD123 as representatives for a hierarchical hematopoietic stem and progenitor cell (HSPC) classification as well as programmed death ligand 1 (PD-L1). Rather than restricting the evaluation on a 2- or 3-dimensional analysis, we applied a t-distributed stochastic neighbor embedding (t-SNE) ap...
Source: Cancers - March 28, 2024 Category: Cancer & Oncology Authors: Cathrin Nollmann Wiebke Moskorz Christian Wimmenauer Paul S. J äger Ron P. Cadeddu J örg Timm Thomas Heinzel Rainer Haas Tags: Article Source Type: research
A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome
Bone Marrow Transplantation, Published online: 27 March 2024; doi:10.1038/s41409-023-02195-xA phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - March 27, 2024 Category: Hematology Authors: Ray Mun Koo Eric Wong Joanne E. Davis Travis Perera Andrew Lim Rachel M. Koldej David S. Ritchie Source Type: research
Cancers, Vol. 16, Pages 1278: Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall Survival: A French & ndash;Italian Experience of 134 Patients
Conclusions: Relapse treatment with a pre-emptive strategy was associated with improved outcomes, particularly when DLI was employed. (Source: Cancers)
Source: Cancers - March 26, 2024 Category: Cancer & Oncology Authors: Eugenia Accorsi Buttini Cristina Doran Michele Malagola Vera Radici Marco Galli Vicky Rubini Alessandro Leoni Mirko Farina Nicola Polverelli Federica Re Simona Bernardi Mohamad Mohty Domenico Russo Eolia Brissot Tags: Article Source Type: research
Toll-Like Receptor 4, 2, and Interleukin 1 Receptor Associated Kinase4: Possible Diagnostic Biomarkers in Myelodysplastic Syndrome Patients
CONCLUSION: Overall, the expression of TLR2, TLR4, and IRAK4 could be potential biomarkers for discriminating MDS from some hematologic disorders.PMID:38525404 | PMC:PMC10958736 | DOI:10.4103/abr.abr_67_23 (Source: Biomed Res)
Source: Biomed Res - March 25, 2024 Category: Research Authors: Parvin Khalilian Nahid Eskandari Mohammad Jafar Sharifi Mohammad Soltani Pardis Nematollahi Source Type: research
Toll-Like Receptor 4, 2, and Interleukin 1 Receptor Associated Kinase4: Possible Diagnostic Biomarkers in Myelodysplastic Syndrome Patients
CONCLUSION: Overall, the expression of TLR2, TLR4, and IRAK4 could be potential biomarkers for discriminating MDS from some hematologic disorders.PMID:38525404 | PMC:PMC10958736 | DOI:10.4103/abr.abr_67_23 (Source: Biomed Res)
Source: Biomed Res - March 25, 2024 Category: Research Authors: Parvin Khalilian Nahid Eskandari Mohammad Jafar Sharifi Mohammad Soltani Pardis Nematollahi Source Type: research
Sustained remission after cord blood transplantation for breast cancer with lung metastases and myelodysplastic syndrome
Int J Hematol. 2024 Mar 25. doi: 10.1007/s12185-024-03762-8. Online ahead of print.ABSTRACTAllogenic hematopoietic stem cell transplantation (allo-HSCT) is not a standard therapy for solid cancer because of its high toxicity and insufficient evidence levels. However, the potential graft-versus-solid-tumor (GVT) effect of this therapy has been discussed. Many case reports have also described treatment effects of allo-HSCT in patients with hematologic malignancies and active solid tumors. A 38-year-old woman treated with fulvestrant and abemaciclib for recurrent breast cancer with multiple lung metastases was diagnosed with ...
Source: International Journal of Hematology - March 25, 2024 Category: Hematology Authors: Naokazu Nakamura Nao Yamamoto Tadakazu Kondo Mayumi Matsumoto Ryo Ikunari Tomomi Sakai Yasuhiro Tanaka Hiroko Tsunemine June Takeda Junya Kanda Yasuhito Nannya Seishi Ogawa Akifumi Takaori-Kondo Nobuyoshi Arima Source Type: research
Sustained remission after cord blood transplantation for breast cancer with lung metastases and myelodysplastic syndrome
Int J Hematol. 2024 Mar 25. doi: 10.1007/s12185-024-03762-8. Online ahead of print.ABSTRACTAllogenic hematopoietic stem cell transplantation (allo-HSCT) is not a standard therapy for solid cancer because of its high toxicity and insufficient evidence levels. However, the potential graft-versus-solid-tumor (GVT) effect of this therapy has been discussed. Many case reports have also described treatment effects of allo-HSCT in patients with hematologic malignancies and active solid tumors. A 38-year-old woman treated with fulvestrant and abemaciclib for recurrent breast cancer with multiple lung metastases was diagnosed with ...
Source: International Journal of Hematology - March 25, 2024 Category: Hematology Authors: Naokazu Nakamura Nao Yamamoto Tadakazu Kondo Mayumi Matsumoto Ryo Ikunari Tomomi Sakai Yasuhiro Tanaka Hiroko Tsunemine June Takeda Junya Kanda Yasuhito Nannya Seishi Ogawa Akifumi Takaori-Kondo Nobuyoshi Arima Source Type: research
Acute lymphoblastic leukemia with pseudo-Chediak-Higashi granules in the initial diagnosis and relapse
We present the case of an 8-year-old boy who was diagnosed with ALL with pseudo-Chediak-Higashi granules in the initial diagnosis and relapse, acting like a characteristic marker.PMID:38516736 | DOI:10.1111/ijlh.14271 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - March 22, 2024 Category: Hematology Authors: Rongjie Li Shimei Xia Yingyan Liao Bailing Zhou Source Type: research
